ABCC9

ABCC9 encodes SUR2, the regulatory subunit that assembles with Kir6.x pore-forming subunits to form ATP-sensitive potassium (KATP) channels coupling cellular metabolic state to membrane excitability (PMID:15034580, PMID:22610116, PMID:22608503). SUR2 harbors intrinsic ATPase activity concentrated in NBD2 and, to a lesser degree, NBD1, whose heterodomain NBD1/NBD2 interaction drives conformational rearrangements that potentiate catalysis and translate nucleotide binding into pore regulation (PMID:18311911). This catalytic cycle decodes intracellular nucleotide signals: ATP binding inhibits the channel while MgADP/MgNDP binding activates it, and disease mutations distort this balance through at least two distinct routes—reduced ATP inhibition or enhanced MgADP activation—both yielding gain-of-function channel opening (PMID:23739550, PMID:26621776, PMID:36336713). Gain-of-function ABCC9 variants cause Cantú syndrome (PMID:22610116, PMID:22608503) and confer susceptibility to arrhythmia, Brugada/early repolarization, and sudden death (PMID:24439875, PMID:30878466), whereas loss-of-function from a homozygous splice variant defines ABCC9-related Intellectual disability Myopathy Syndrome (AIMS) with cardiac dysfunction in mouse and zebrafish models (PMID:31575858). Beyond excitability, ABCC9 is required for the neonatal cardiac transition to oxidative mitochondrial metabolism (PMID:24648545), and the KCNJ8/ABCC9 channel cell-autonomously regulates brain vascular smooth muscle differentiation through Ca2+ oscillation (PMID:35588738). ABCC9 transcription is controlled by CpG methylation of its promoter (PMID:22844491) and by a TRIM11/Daple/β-catenin axis that drives multidrug resistance in nasopharyngeal carcinoma (PMID:32382014).

1. 2004 High

   Established that ABCC9 disease mutations cluster near the SUR2A catalytic ATPase pocket and act by distorting the intrinsic ATP hydrolytic cycle, defining defective catalysis-mediated pore regulation as a disease mechanism.

   Evidence Genomic DNA scanning plus ATPase and electrophysiology assays of mutant SUR2A

   PMID:15034580

   Open questions at the time

   • Did not resolve the structural basis of how catalysis gates the Kir6 pore
   • Specific clinical phenotype-mutation correlations not yet established
2. 2008 High

   Localized SUR2A ATPase activity to the nucleotide-binding domains and showed the asymmetric NBD1/NBD2 heterodomain interaction potentiates catalysis, explaining how nucleotide sensing is mechanically organized.

   Evidence Purified recombinant NBD1/NBD2 domains analyzed by AFM, TEM, circular dichroism, ATPase assays and D834E mutagenesis

   PMID:18311911

   Open questions at the time

   • Domain studies done in isolation, not in intact assembled channel
   • Link from NBD conformational change to pore gating inferred, not directly visualized
3. 2012 High

   Identified ABCC9 gain-of-function mutations reducing ATP inhibition as the cause of Cantú syndrome, establishing a human disease driven by excess KATP channel opening.

   Evidence Family-based and trio exome sequencing with electrophysiology of mutant channels; independent replication

   PMID:22608503 PMID:22610116

   Open questions at the time

   • Tissue-specific contributions of different SUR2 splice variants not resolved
   • Mechanism by which transmembrane-domain mutations alter ATP sensitivity not structurally defined
4. 2013 High

   Demonstrated splice-variant- and tissue-specificity of ABCC9 channel dysfunction, showing the V734I variant selectively impairs vascular (SUR2B) nucleotide responses linked to coronary spasm.

   Evidence Inside-out patch-clamp of mutant channels across SUR2A/SUR2B/Kir6.x combinations in oocytes and HEK cells

   PMID:23739550

   Open questions at the time

   • In vivo vascular phenotype of the variant not tested
   • Did not address why the same variant is benign in cardiac channels mechanistically
5. 2014 Medium

   Broadened the arrhythmia spectrum by showing ABCC9 gain-of-function variants underlie Brugada and early repolarization syndromes via increased IK-ATP.

   Evidence Whole-cell and inside-out patch-clamp of mutant channels in TSA201 cells with sequencing

   PMID:24439875

   Open questions at the time

   • Single lab, small patient cohort
   • Causality at the organismal/clinical level not established
6. 2014 High

   Revealed a metabolic role beyond excitability, showing Abcc9 is required for the neonatal heart's switch from glycolytic to oxidative mitochondrial metabolism.

   Evidence Abcc9 knockout mouse with mitochondrial membrane potential, fatty acid oxidation, oxygen consumption assays, diazoxide stimulation and electron microscopy

   PMID:24648545

   Open questions at the time

   • Molecular link between sarcolemmal KATP channel function and mitochondrial maturation unresolved
   • Whether the effect is channel-dependent or independent not dissected
7. 2015 High

   Resolved that Cantú gain-of-function arises through at least two mechanistically distinct routes—enhanced MgADP activation versus decreased ATP inhibition—clarifying the molecular heterogeneity of a single syndrome.

   Evidence 86Rb+ efflux and inside-out patch-clamp of multiple Cantú mutants coexpressed with Kir6.2 in oocytes

   PMID:26621776

   Open questions at the time

   • Whether the two mechanisms produce distinct clinical severity not addressed
   • Structural correlates of each mechanism not defined
8. 2019 High

   Defined the loss-of-function end of the ABCC9 spectrum, showing a splice variant producing non-functional channels causes the AIMS syndrome with conserved phenotypes across species.

   Evidence Recombinant channel assays plus mouse and zebrafish phenotyping with patient exome sequencing

   PMID:31575858

   Open questions at the time

   • Mechanism linking SUR2 loss to intellectual disability/myopathy not detailed
   • Cell types driving each phenotypic feature not isolated
9. 2019 Medium

   Connected rare ABCC9 variants to sudden unexpected death by showing they enhance open-state probability without altering unitary current or surface expression.

   Evidence Patch-clamp and surface biotinylation of human SUR2A + Kir6.2 in HEK-293 cells

   PMID:30878466

   Open questions at the time

   • Single lab, no replication
   • Direct causal contribution to death events not established
10. 2022 High

    Uncovered a developmental role in which the KCNJ8/ABCC9 channel cell-autonomously controls brain vascular smooth muscle differentiation via Ca2+ oscillation, linking the channel to neurovascular coupling.

    Evidence Mouse and zebrafish genetics, cell culture, pharmacology, Ca2+ imaging and neurovascular coupling measurements

    PMID:35588738

    Open questions at the time

    • Why this regulation is brain-selective not fully explained
    • Connection to Cantú vascular phenotypes not directly tested
11. 2022 Medium

    Added an in-frame deletion gain-of-function variant with increased ATP IC50, extending the catalogue of ATP-inhibition-impairing mutations.

    Evidence Inside-out patch-clamp of mutant SUR2A + Kir6.2 in Cosm6 cells

    PMID:36336713

    Open questions at the time

    • Single variant, single lab, no replication
    • Clinical phenotype not functionally tied to the variant
12. 2024 Medium

    Assigned a functional role to the first glycine of the ABC NBD signature motif by showing a SUR2B variant there causes gain-of-function with reduced ATP sensitivity.

    Evidence Stable hKir6.1 + hSUR2B mutant expression with membrane potential and inside-out patch-clamp

    PMID:39031464

    Open questions at the time

    • Single variant, single lab
    • Structural mechanism by which the signature-motif glycine controls ATP gating not resolved
13. 2025 Medium

    Placed ABCC9 upstream of PI3K/AKT signaling in cardiomyocyte hypertrophy, showing knockdown reduces apoptosis and oxidative stress dependent on this pathway.

    Evidence siRNA knockdown in AC16 cardiomyocytes with western blot, mitochondrial and ROS/apoptosis assays and pharmacological rescue with 740Y-P

    PMID:41347799

    Open questions at the time

    • Single lab, no replication
    • Whether the effect requires channel activity versus a non-channel role unclear
    • In vivo relevance not tested
14. 2020 Medium

    Identified a transcriptional regulatory axis in which TRIM11/Daple/β-catenin drives ABCC9 expression to confer multidrug resistance in nasopharyngeal carcinoma.

    Evidence qRT-PCR, Co-IP, ubiquitination and promoter binding assays with in vitro and in vivo cisplatin resistance models

    PMID:32382014

    Open questions at the time

    • ABCC9 as downstream effector; direct drug-efflux role not demonstrated here
    • Single lab; generality across cancers not tested

• How catalytically driven NBD conformational changes are mechanically transmitted to gate the Kir6 pore in the assembled channel, and how the same molecule's metabolic and developmental roles relate to its channel function, remain unresolved.
• No structural model of mutation-to-gating coupling in intact octamer
• Channel-dependent vs channel-independent contributions to metabolic/developmental phenotypes undissected
• Tissue-specific splice-variant roles incompletely mapped